文献速递慢性静脉疾病

肥胖的CEAP C2和C3疾病患者在接受腔内热消融后症状改善更明显

Obese patients with CEAP (clinical, etiology, anatomy, pathophysiology) C2 and C3 disease show enhanced symptom improvement after endovenous thermal ablation.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2024-03-19

基于血管质量倡议数据库回顾性分析2015年1月至2021年12月因CEAP C2或C3行腔内热消融的8146条肢体,肥胖组2963条(36.4%)、非肥胖组5183条(63.6%)。肥胖组HASTI评分改善更大(-7.24 vs -6.62,P<.001),VCSS改善无差异(-3.29 vs -3.35,P=.408),浅表血栓性静脉炎发生率更高(1.5% vs 0.7%,P=.001)。

要点

  • 肥胖组与非肥胖组VCSS改善无显著差异(-3.29 vs -3.35,P=.408)。
  • 肥胖组HASTI评分改善大于非肥胖组(-7.24 vs -6.62,P<.001)。
  • 肥胖组浅表血栓性静脉炎发生率高于非肥胖组(1.5% vs 0.7%,P=.001)。

核心结论

  • 数据提示肥胖的CEAP C2或C3患者接受腔内热消融后感知症状改善更大,临床改善和并发症与非肥胖患者差异不大。
  • 作者指出尽管肥胖与静脉疾病症状严重程度增加相关,肥胖患者在短期治疗后能获得显著缓解,且在较轻疾病表现时治疗可能获得比非肥胖患者更大的症状缓解。

研究设计与样本

  • 利用血管外科学会血管质量倡议数据库回顾性分析2015年1月至2021年12月所有CEAP临床分级C2或C3接受腔内热消融患者的初次手术。
  • 共纳入8146条肢体,按体重指数≥30 kg/m2分为肥胖组2963条(36.4%)和非肥胖组5183条(63.6%)。
  • 主要结局为从手术至初次随访的静脉临床严重程度评分变化,次要结局包括HASTI评分变化、随访并发症发生率和治疗静脉再通。
  • VCSS和HASTI评分变化采用Student t检验分析,并发症和再通采用Fisher精确检验评估,显著结局通过多变量logistic回归确认,肥胖按世界卫生组织分类系统分析。

主要发现

  • 肥胖对VCSS改善无影响(-3.29 vs -3.35;P = .408)。
  • 肥胖与整体症状更大改善相关,表现为HASTI评分改善更大(-7.24 vs -6.62;P < .001)。
  • 肥胖肢体浅表血栓性静脉炎发生率更高(1.5% vs 0.7%;P = .001),再通或其他并发症无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Endovenous thermal ablation (EVTA) is a prevalent treatment option for patients with severe venous disease. However, the decision to intervene for patients with less severe disease (CEAP [clinical, etiology, anatomy, pathophysiology] C2 and C3) is less clear and becomes further complicated for patients with obesity, a pathology known to increase venous disease symptom severity. Therefore, the objective of this study was to use the Society for Vascular Surgery Vascular Quality Initiative database to evaluate outcomes after EVTA in obese patients with CEAP C2 and C3 venous insufficiency. METHODS: Using the Society for Vascular Surgery Vascular Quality Initiative database, we retrospectively analyzed the initial procedure of all patients with a CEAP clinical class of C2 or C3 who underwent EVTA from January 2015 to December 2021. Patients were grouped by obesity, defined as a body mass index of ≥30 kg/m2. The primary outcome was the change in venous clinical severity score (VCSS) from the procedure to the patient's initial follow-up. The secondary outcomes included the change in patient-reported outcomes at follow-up via the HASTI (heaviness, achiness, swelling, throbbing, itching) score, incidence of follow-up complications, and recanalization of treated veins. The change in the VCSS and HASTI score were analyzed using Student t tests, and complications and recanalization were assessed using the Fisher exact test. Significant outcomes were confirmed by multiple variable logistic regression. The remaining significant variables were then analyzed, with obesity categorized using the World Health Organization classification system to analyze how increasing obesity levels affect outcomes. RESULTS: There were 8146 limbs that met the inclusion criteria, of which 5183 (63.6%) were classified as nonobese and 2963 (36.4%) as obese. Obesity showed no impact on improvement in the VCSS (-3.29 vs -3.35; P = .408). Obesity was found to be associated with a larger improvement in overall symptoms, as evidence by a greater improvement in the HASTI score (-7.24 vs -6.62; P < .001). Obese limbs showed a higher incidence of superficial phlebitis (1.5% vs 0.7%; P = .001), but no difference was found in recanalization or any other complication. CONCLUSIONS: These data suggest that obese patients with CEAP clinical class C2 or C3 experience greater improvement in their perceived symptoms after EVTA with little difference in clinical improvement and complications compared with nonobese patients. Although obesity has been associated with increased severity of venous disease symptoms, obese patients are able to derive significant relief after treatment during the short term and may experience greater relief of symptoms than nonobese patients when treated at more mild disease presentations.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Zottola ZR, Geiger JT, Choo GE, et al. Obese patients with CEAP (clinical, etiology, anatomy, pathophysiology) C2 and C3 disease show enhanced symptom improvement after endovenous thermal ablation. J Vasc Surg Venous Lymphat Disord. 2024. PMID: 38513798. doi:10.1016/j.jvsv.2024.101873

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。